Fostemsavir (Rukobia®)
Fostemsavir (Rukobia®) for the treatment of adults with multi-drug resistant human immunodeficiency virus-1 for whom it is not possible to construct a suppressive anti-viral regimen, is available from December 2024.
A Managed Access Protocol (MAP) is in place for fostemsavir (Rukobia®). This outlines the criteria that must be satisfied in order for a patient to be recommended for approval of funding for fostemsavir (Rukobia®).
Applications for funding approval for fostemsavir for the treatment of multi-drug resistant human immunodeficiency virus-1 under hospital pricing approval will only be considered from consultants, with specialist registration with the Irish Medical Council in the speciality of infectious diseases or genitourinary medicine, practicing in a designated centre, and who have agreed to the terms of this MAP and been approved by the HSE.
The approved consultant must submit an application for individual funding approval for each patient. Applications for individual funding approval will only be considered from approved consultants.
A copy of the MAP for fostemsavir (Rukobia®) and application form for individual funding approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.